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Introduction
Among European women, ovarian cancer is the fifth most 
common cancer with more than 70,000 new cases recorded 
in 2012 [1]. Recently, a large European population study 
estimated that almost one in five new cancers are caused 
by cigarette smoking [2] while another report from the 
United Kingdom estimated that 2.6% of overall ovarian 
cancer cases are attributable to smoking [3]. In 2012, the 
International Agency for Research on Cancer classified 
mucinous ovarian tumors as causally related to tobacco 
smoking based on results from twenty different epide-
miological studies [4].
The Norwegian Women and Cancer Study (NOWAC) 
is a nationally representative prospective cohort providing 
a unique setting to estimate both the prevalence of smok-
ing and the relationship of smoking and subtypes of 
epithelial ovarian cancer. We aimed to estimate the impact 
of smoking on epithelial ovarian cancers (EOC) using 
population attributable fractions (PAFs) of subtypes of 
EOC, by invasiveness status EOC and by histological sub-
types in the NOWAC study.
Material and Methods
NOWAC study
The NOWAC is a national representative prospective co-
hort study initiated in 1991. The cohort has been described 
elsewhere [5, 6]. Briefly, the Central Population Register 
selected a random sample of women according to year 
of birth. Subsequently, an invitation to participate in the 
study, with a baseline questionnaire and prestamped return 
envelope enclosed was mailed to these women. The 
NOWAC study was approved by the Regional Committee 
for Medical Research Ethics and the Norwegian Data 
Inspectorate. All women gave written informed consent 
(http://site.uit.no/nowac).
Women aged 34–70 years who completed a baseline 
questionnaire on lifestyle factors during three waves of 
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Abstract
Among European women, ovarian cancer is the fifth most common cancer. 
Smoking is an established risk factor for mucinous tumors. We estimated the 
impact of smoking in Norwegian women using population attributable fractions 
(PAFs) of epithelial ovarian cancer (EOC), by invasiveness and by histological 
subtypes in the Norwegian Women and Cancer Study with an average of 13.2 years 
of follow- up. During >2 million person- years, a total of 915 incident EOC 
cases, of which 667 (73%) invasive and 248 (27%) borderline, were identified 
among 154,234 women aged 34–70 years at enrolment. Compared with never 
smokers, current smokers had a nonstatistically significant increased risk of 
mucinous tumors (hazard ratio [HR] = 1.67 [95% confidence interval, (CI), 
0.96–2.96]) and more than twice statistically significant risk of borderline 
 mucinous tumors (HR = 2.17 [95% CI, 1.06–4.45]). The corresponding PAF 
estimates were 16.5% for mucinous and 25% for borderline mucinous. We 
found that among middle- aged women, one in six mucinous tumors and one 
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data collection: 1991–1992, 1996–1997, and 2003–2007 
(N = 172,539) were included. New women were recruited 
in each wave. We excluded women with prevalent cancer 
at baseline (except nonmelanoma skin cancer) (N = 6964), 
who emigrated or died before start of follow- up (N = 80), 
with bilateral oophorectomy (N = 5760), who were born 
after 1957 (N = 3167) since they did not receive complete 
questionnaires, who emigrated after enrolment, but were 
diagnosed with cancer afterward (N = 13) and those with 
missing information on smoking status (N = 2260). The 
analytical cohort comprised the remaining women 
(N = 154,234).
The women reported if they have smoked, number of 
cigarettes smoked daily at different ages, and if they cur-
rently smoked daily. Women who had never smoked and 
reported no exposure to smoking in their childhood home 
were categorized as never smokers; those passively exposed 
to smoke during childhood were classified as passive smok-
ers. We did not have complete information on passive 
smoking in adulthood. We categorized the women as 
current, former, passive, and never smokers based on this 
information.
Information on cancer incidence, emigration and deaths 
were obtained through linkages to the Cancer Registry 
of Norway (http://www.kreftregisteret.no/en) and 
Norwegian Central Population Register, respectively. The 
overall estimated completeness of the Cancer Registry of 
Norway has been shown to be more than 98% [7].
Person- years were calculated from start of follow- up 
until the date of any incident cancer diagnosis (except 
nonmelanoma skin cancer), emigration, death, or the end 
of follow- up (31 December 2012), whichever occurred 
first. Epithelial ovarian cancer cases were classified using 
the International Classification of Diseases, ICD- 7 (loca-
tion 175) and ICD- O- 3 (tumor subtype) codes. Invasive 
and borderline surface epithelial–stromal ovarian tumors 
are here referred to as EOC.
Statistical analysis
Cox proportional hazards models with age as the 
 underlying time scale were used to estimate multivariable- 
adjusted HRs with 95% confidence intervals (CI) for the 
associations between smoking exposure (passive, former, 
current) and EOC stratified by invasiveness and histologi-
cal subtypes (serous, mucinous). Similar models were 
used to estimate multivariable- adjusted HRs with 95% 
CI for the associations between different measures of 
smoking exposure (passive, former, current); and for 
 current smokers; (age at smoking initiation [<20, 
20+ years], smoking duration [≤20, 20+ years], number 
of pack- years [<10, 10+], number of cigarettes smoked 
per day [<10, 10+]), and EOC overall and stratified by 
invasiveness and histological subtypes. We analyzed serous, 
mucinous and, endometrioid subtypes as separate groups 
and the remaining tumors, including clear cell, as “oth-
ers”; we did not have enough cases of clear cell subtype 
to analyze this as a separate group. Never smokers were 
used as reference group.
Each of the following factors was found to be a  potential 
confounder and included in the final model: age at 
 menarche (≤12, >12 years), number of full- term pregnan-
cies (0, 1 or 2, 3+), age at first full- term pregnancy 
 (nulliparous, ≤19, >19–24, >24–29, and ≥30 years), age 
at last birth (≤24, >24–29, >29–33, and ≥34 years),  infertility 
(yes, no, missing [n = 9625]) menopausal status (pre- or 
perimenopausal, postmenopausal, hysterectomy before 
53 years, hormonal replacement therapy use before 53, 
missing [n = 3723]), age at menopause (≤45, >45- 50, 
>50–52, ≥53 years), educational attainment (≤9, >9–12, 
>12–16, ≥17 years, missing [7915]), physical activity score 
(scored as 1–5 low to high level, missing [n = 12,644]), 
alcohol intake (teetotalers, ≤4, >5–9, and, ≥10 g/day, miss-
ing [n = 8058]), BMI (≤18.49, >18.49–24.9, >24.9–29.9, 
≥30 kg/m2, and missing [n = 3594]), oral contraceptive 
use (yes, no, missing [n = 5182]), duration of oral 
 contraceptive use (≤3, >3–7, ≥8 years), hormonal replace-
ment therapy (yes, no, missing [n = 30,864]), age at start 
using hormonal replacement therapy (≤45, >45–49, 
≥50 years). We included missing indicators specific to 
confounding factors after checking that the parameters 
associated with these indicators were not associated with 
the different outcomes.
An ordinal exposure variable with equally spaced scores, 
which included never smokers, was created to test for 
linear trends. Wald chi- square statistics were used to test 
for heterogeneity between different histological tumors 
types and according to the invasiveness status. Models 
were stratified by enrolment waves in order to control 
for differences in questionnaire design and follow- up time. 
Schoenfeld residuals were used to test the proportional 
hazards assumptions. Effect modification in the relation 
between smoking status (never, passive, former and cur-
rent) and EOC by, in turn, alcohol consumption (con-
tinuous), educational attainment, BMI and menopausal 
status (yes, no), and number of children was assessed. 
Models with main effects and interaction terms were fitted 
and compared with models with main effects only. The 
difference in log- likelihood (likelihood ratio test statistics) 
was compared to a χ2 distribution with degrees of freedom 
equal to the number of interaction terms.
We calculated the PAF in order to estimate the pro-
portion of EOC subtypes that would not occur if smoking 
were eliminated. The prevalence of smoking in the 
 nationally representative NOWAC study was assessed and 
multivariable- adjusted HRs were used as valid estimates 
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of relative risks. The formula described in the WHO global 
report [8], was used to compute PAFs:
where the notation Pe is the proportion of persons in 
the population exposed to the risk factor, that is, ever 
smokers and RRe is the relative risk in the exposed 
compared to unexposed group; that is, ever smokers 
compared with never smokers in the final multivariable 
proportional hazards regression model, including all 
 previously listed covariates. We calculated the two- sided 
95% CI’s for the PAFs using the PUNAF Stata module 
[9]. The analyses were performed with SAS- version 9.4 
(SAS Institute, Cary, NC, USA)/STATA- version 13.1 (Stata 
Corp, College Statistics, TX, USA).
Results
During >2 million person- years with an average follow- up 
time of 13.2 years, a total of 915 EOC cases (667 [73%] 
invasive and 248 [27%] borderline) were identified. The 
cases were classified as either serous (n = 554, [61%]), 
mucinous (n = 126, [14%]), endometrioid (n = 59, [6%]), 
or others (n = 176, [19%]). Table S1 shows that 30.8% 
of women were current, 34.5% former, and 18.0% passive 
smokers and the remaining 16.7% were never smokers.
Table 1 shows that compared with never smokers, cur-
rent smokers had a significantly increased risk of borderline 
tumors of 69% (HR = 1.69 [95% CI 1.10–2.61]). The 
corresponding PAF attributed to current smoking was 17.2% 
(95% CI 3.8–28.7). The HR and PAF estimations in overall 
mucinous tumors when current smokers were compared 
to never were HR = 1.67 (95% CI 0.96–2.96), and 
PAF = 16.5% (95% CI −1.8–31.5). Current smokers who 
had smoked 20 or more years also had increased HR es-
timates compared with never smokers for the five outcomes, 
of which EOC overall (HR = 1.29 [95% CI 1.03–1.62], 
Ptrend = 0.02), and borderline (HR = 1.85 [95% CI 1.16–
2.95], Ptrend = 0.01) tumors were significant (Table 1).
When current were compared with never smokers the 
HR estimates for endometrioid and “other” tumors were 
nonsignificantly decreased with 6% (HR = 0.94 [0.41–2.12]) 
and increased with 17% (HR = 1.17 [95% CI 0.75–1.85]), 
respectively.
Table 2 shows the serous and mucinous subtype cat-
egories stratified into invasive and borderline tumors: only 
the risk of borderline mucinous was significantly increased 
(HRcurrent vs never = 2.17 [95% CI 1.06–4.45]). The PAF 
attributed to current smoking was 24.7% (95% CI 3.8–28.7) 
for borderline mucinous tumors.
The multivariable- adjusted HR’s for current versus never 
smokers were significantly different between invasive and 
borderline tumors (Pheterogeneity = 0.04). None of the 
 interactions tested between smoking status and alcohol 
consumption, educational attainment, BMI, menopausal 
status, and number of children were significant.
Discussion
We found a statistically significant increased risk of bor-
derline mucinous tumors in current smokers compared 
to never smokers. Current smoking was estimated to be 
responsible for one in four borderline mucinous 
tumors.
We calculated the PAFs and studied the effect of  different 
measures of smoking exposures and found evidence of a 
dose- response association between smoking duration and 
risks of overall EOC and risks of borderline tumors in 
current smokers.
Strengths of our study include the prospective and 
population- based design, the large sample size, the long 
follow- up time, the national population- based registries, 
and detailed information on smoking history including 
passive smoking exposure. Moreover, the smoking exposure 
[10] and cancer incidence [5] are nationally representa-
tive, justifying the PAF estimation.
A limitation of our study is that updated information 
on smoking status was not considered in this analysis 
because that information was only available in a reduced 
simple size. In Norway, the proportion of daily smokers 
has decreased steadily from 36.5% in 1991 to 18.5% in 
2012 [11]. In our study, the estimated prevalence of smok-
ing was based on information collected between 1991 and 
2007 (three waves of enrolment). Therefore, the decrease 
in smoking prevalence during this period is reflected in 
our data. However, as the majority of NOWAC women 
were recruited during the first wave of data collection 
(1991–1992), the decrease in smoking prevalence over time 
was only partially reflected in our PAFs estimates. This 
may result in overestimated PAFs of smoking. However, 
any possible misclassification in smoking status (current 
to former, former to current, never to current) would 
attenuate the displayed associations between current smok-
ing and risk of EOC.
Another limitation of our study is the possible misclas-
sification of histological types of EOC and invasiveness. 
We believe that a differential misclassification of EOC 
subtypes between current and never smokers is unlikely. 
In addition, we observe significant differences between 
invasive and borderline tumors, which is nonsupporting 
substantial misclassification in our data as this would have 
diluted the differences.
Borderline tumors are more common in younger women 
and have a much better prognosis than invasive tumors 
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in the last years in Nordic countries while the incidence 
of invasive ovarian carcinoma has decreased [13, 14]. 
Hysterectomy with double adnexectomy is the recom-
mended treatment in the presence of borderline tumors 
[15]. This is considered invasive surgery, and for young 
women, this treatment has the serious consequence that 
they no longer can bear children.
With a larger number of mucinous cases, we found a 
similar risk and PAF estimation in mucinous tumors as a 
study from the European Prospective Investigation into 
Cancer and nutrition (EPIC) [2] that found 14% of mu-
cinous ovarian cancer to be attributable to smoking. Unlike 
our cohort, the authors pointed out that EPIC is not a 
representative sample. To the best of our knowledge, the 
only other study reporting PAFs of overall ovarian cancer 
attributable to smoking [3], found this to be 2.6% of cases.
The interpretation of PAFs as the proportion of tumors 
that could be avoided if women did not smoke is justified 
when an established causal relationship exists as between 
smoking and mucinous tumors. We therefore also have 
estimated this PAF value although the corresponding HR 
estimate was not significantly increased in this study.
Our results are in agreement with respect to two recent 
meta- analyses, the 51 epidemiological studies [16], and a 
recent pooled analysis of 21 case–control studies [17]. As 
did we, the meta- analysis of 51 epidemiological studies 
with >17,000 ovarian cancer cases found a more than 
double risk of mucinous borderline tumors for current 
compared with never smokers [16] and the pooled analysis 
of 21 case–control studies [17], found an odds ratio of 
1.83 (95% CI 1.39–2.41).
In line with other previous studies [18, 19], we ob-
served a borderline increased risk in mucinous tumors 
when comparing current to never smokers. This is 
explained both by an increased risk of borderline mu-
cinous tumors and a nonassociation in invasive mucinous 
Table 2. Multivariable1 hazard ratios (95% confidence interval) of serous and mucinous epithelial ovarian cancer overall by invasive status according 
to various measures of smoking status at enrollment compared with never smokers in NOWAC study 1991–2012 (N = 153,234).
Invasive tumors Borderline tumors
Cases Serous N = 397 Cases Mucinous N = 43 Cases Serous N = 157 Cases Mucinous N = 83
Smoking exposure
 Never 72 1 7 1 19 1 9 1
 Passive 72 0.96 (0.69–1.34) 8 1.01 (0.38–2.96) 26 1.17 (0.64–2.14) 15 1.49 (0.65–3.41)
 Former 128 0.98 (0.74–1.32) 13 0.97 (0.36–2.60) 44 0.99 (0.56–1.75) 19 1.12 (0.50–2.52)
 Current 125 0.99 (0.73–1.35) 15 1.02 (0.38–2.79) 68 1.46 (0.84–2.53) 40 2.17 (1.06–4.45)
Smoking duration (years)3,4
 0–19 118 1.06 (078–1.44) 11 0.96 (0.36–2.55) 35 0.91 (0.51–1.62) 24 1.47 (0.67–3.27)
 20+ 135 1.04 (0.77–1.42) 17 1.12 (0.44–2.88) 77 1.59 (0.93–2.72) 35 1.97 (0.90–4.30)
 Ptrend
2 0.82 0.75 0.02 0.07
Pack- years of smoking3,4
 0–9 138 1.04 (0.75–1.35) 16 1.08 (0.43–2.71) 52 1.11 (0.64–2.91) 29 1.48 (0.68–3.22)
 10+ 115 1.13 (0.82–1.56) 12 0.99 (0.37–2.69) 60 1.47 (0.85–2.56) 30 2.11 (0.95–4.69)
 Ptrend
2 0.39 0.96 0.10 0.05
Age at smoking initiation3,4
 20+ 71 0.92 (0.58–1.15) 15 0.87 (0.26–1.88) 23 0.96 (0.45–1.58) 19 1.59 (0.73–3.49)
 0–19 176 1.22 (0.90–1.64) 13 1.62 (0.64–4.11) 89 1.58 (0.93–2.71) 37 1.57 (0.69–3.55)
 Ptrend
2 0.12 0.30 0.18 0.23
Number of cigatettes/day3,4
 0–9 102 1.02 (0.76–1.39) 13 0.85 (0.33–2.20) 77 1.23 (0.72–2.11) 31 1.57 (0.72–3.40)
 10+ 139 1.07 (0.77–1.48) 13 1.31 (0.49–3.49) 58 1.36 (0.78–2.38) 25 1.67 (0.74–3.78)
 Ptrend
2 0.68 0.48 0.29 0.26
1Adjusted for age at menarche (≤12, >12 years), number of full- term pregnancies (0, 1 or 2, 3+), age at first full- term birth (nulliparous, ≤19, >19–24, 
and >24–29, ≥30 years), age at last birth (≤24, >24–29, >29–33, ≥34 years), infertility (yes, no, missing) menopausal status (postmenopausal pre- or 
perimenopausal, hysterectomy before 53 years, hormonal replacement therapy use before 53, missing), age at menopause (≤45, >45–50, >50–52, 
≥53 years), educational attainment (≤19, >9–12, >12–16, ≥17 years, missing), physical activity score (scored as 1–5 low to high level, missing), alcohol 
intake (teetotalers, ≤4, >5–9, and, ≥10 g/day, missing), BMI (≤18.49, >18.49–24.9, >24.9–29.9, ≥30 kg/m2, missing), oral contraceptive use (yes, no, 
missing), duration of oral contraceptive use (≤3, >3–7, ≥8 years), hormonal replacement therapy (yes/no, missing), age at start using hormonal re-
placement therapy (≤45, >45–49, ≥50 years).
2Trend tests include never smokers.
3In the respective models, additional missing in the main exposures qualifying smokers among ever smokers were excluded (age at start smoking 
Nmissing = 1241, pack- year Nmissing = 19, average number of cigarettes smoked per day Nmissing = 4418, duration of smoking in years Nmissing = 19).
4Among ever smokers.
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tumors. Although, with fewer mucinous cancer cases 
than in our present study, other studies have reported 
a statistically significant increased risks for mucinous 
tumors [16, 20–22]. Nonetheless, when we stratify by 
invasiveness and histological subtype, a limitation is 
that we have few cases, especially for the mucinous 
tumors.
One plausible explanation for a stronger association 
between smoking and borderline tumors than invasive 
tumors is that somatic mutations in the KRAS gene are 
common in borderline tumors than in invasive, and are 
more frequent in mucinous compared to serous borderline 
ovarian tumors [23]. Smoking- induced KRAS mutations 
have been found in lung, pancreatic, and colon cancers 
[24–26], and a similar mechanism of oncogenesis might 
be applicable to borderline tumors.
In conclusion, among middle- aged women, one in six 
mucinous tumors and one in four borderline mucinous 
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